Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 113

Sort by

Sort Order Select

Journal Articles

Treatment responses and survival of newly diagnosed older or unfit patients (pts) with IDH1/2-mutated Acute Myeloid Leukemia (AML): An analysis of the MARROW consortium

Blood (2025) 146 (Supplement 1): 1626.

https://doi.org/10.1182/blood-2025-1626

Published: 2025

Journal Articles

Loss of the Y chromosome defines a biologically distinct subtype of Acute Myeloid Leukemia (AML), associated with decreased inflammatory response patterns, and favorable outcomes in young male patients (pts)

Blood (2025) 146 (Supplement 1): 1723.

https://doi.org/10.1182/blood-2025-1723

Published: 2025

Journal Articles

Accounting for long-term survivors and population-expected survival improves survival outcomes estimation and prediction in older patients with core-binding factor (CBF) Acute Myeloid Leukemia (AML)

Justice Ameyi, Deedra Nicolet, Michael Walker, Krzysztof Mrózek, Ann-Kathrin Eisfeld, Kellie Archer

Blood (2025) 146 (Supplement 1): 2584.

https://doi.org/10.1182/blood-2025-2584

Published: 2025

Journal Articles

Phenotypic shift from primitive to monocytic immunophenotype is unique to patients treated with azacitidine + venetoclax (AZA/VEN) and associated with worse outcomes in AML

Daniel Peters, Diana Abbott, Jingjing Zhang, Jacob Fang, Zenggang Pan, Jeffrey Schowinsky, Jonathan Gutman, Andrew Kent, Mathew Angelos, Christine McMahon, Maria Amaya, Marc Schwartz, Wei Xie, Jonathan Galeotti, Jill Buss, Ann-Kathrin Eisfeld, Curtis Lachowiez, Joshua Zeidner, Daniel Pollyea

Blood (2025) 146 (Supplement 1): 3377.

https://doi.org/10.1182/blood-2025-3377

Published: 2025

Journal Articles

Toxicity of reduced dose versus standard dose pegaspargase in adolescents and young adults with acute lymphoblastic leukemia

Blood (2025) 146 (Supplement 1): 3344.

https://doi.org/10.1182/blood-2025-3344

Published: 2025

Journal Articles

Characteristics and clinical outcomes of patients (pts) with Acute Myeloid Leukemia (AML) with Mecom rearrangements: An analysis from the MARROW consortium

Blood (2025) 146 (Supplement 1): 294.

https://doi.org/10.1182/blood-2025-294

Published: 2025

Journal Articles

Defining the clinical characteristics and outcomes of adult patients (pts) with 11q23/KMT2A-rearranged Acute Myeloid Leukemia (AML): An analysis from the MARROW consortium

Blood (2025) 146 (Supplement 1): 292.

https://doi.org/10.1182/blood-2025-292

Published: 2025

Journal Articles

A randomized study of conventional chemotherapy +/- uproleselan in older adults with Acute Myeloid Leukemia eceiving intensive induction chemotherapy (Alliance A041701)

Blood (2025) 146 (Supplement 1): 3415.

https://doi.org/10.1182/blood-2025-3415

Published: 2025

Journal Articles

Evaluation of cytarabine consolidation dosing in older adult patients with Acute Myeloid Leukemia

Pooja Kumar, Deedra Nicolet, Tracelyn Freeman, Lexus Frazier, Allyson Waller, Megan Fleming, Michael Walker, Gregory Behbehani, James Blachly, Uma Borate, Nicole Grieselhuber, Shivani Handa, Jayanshu Jain, Karilyn Larkin, Meixiao Long, Ann-Kathrin Eisfeld, Alice Mims

Blood (2025) 146 (Supplement 1): 3408.

https://doi.org/10.1182/blood-2025-3408

Published: 2025

Journal Articles

A multicenter real-world study on response and survival in older patients with acute myeloid leukemia treated with intensive chemotherapy versus VEN/HMA by 2022 and 2024 ELN risk stratifications: An analysis from the MARROW consortium

Blood (2025) 146 (Supplement 1): 5157.

https://doi.org/10.1182/blood-2025-5157

Published: 2025

Journal Articles

Deep learning predicts IDH1 mutation status in Acute Myeloid Leukemia from bone marrow smear images

Jan-Niklas Eckardt, Ishan Srivastava, Chethan Babu, Sebastian Riechert, Tim Schmittmann, Susann Winter, Martin Schneider, Markus Badstübner, Ann-Kathrin Eisfeld, Haley Roberts, Christoph Röllig, Martin Bornhäuser, Jan Moritz Middeke, Andrew Srisuwananukorn

Blood (2025) 146 (Supplement 1): 2558.

https://doi.org/10.1182/blood-2025-2558

Published: 2025

Journal Articles

Increased yield of recurrent structural variants (SVs) in Ph-like B-cell acute lymphoblastic leukemia (B-ALL) using a streamlined clinical whole-genome sequencing (WGS) assay

Blood (2025) 146 (Supplement 1): 1590.

https://doi.org/10.1182/blood-2025-1590

Published: 2025

Journal Articles

Tri-partied analyses define clinical outcomes and molecular features of patients (pts) with acute promyelocytic leukemia (APL)

Blood (2025) 146 (Supplement 1): 8183.

https://doi.org/10.1182/blood-2025-8183

Published: 2025

Journal Articles

Acute myeloid leukemias with UBTF tandem duplications respond to combined BCL-2 and RNA polymerase I inhibition with increased stemness and a quiescent-like state

Patrick Stelmach, Nesrine Aroua, Dawn Lin, Elisa Donato, Ann-Kathrin Eisfeld, Christoph Röllig, Christian Thiede, Andreas Trumpp

Blood (2025) 146 (Supplement 1): 342.

https://doi.org/10.1182/blood-2025-342

Published: 2025

Journal Articles

Exploiting RAS pathway addiction as a therapeutic vulnerability in myeloid sarcoma

Blood (2025) 146 (Supplement 1): 220.

https://doi.org/10.1182/blood-2025-220

Published: 2025

Journal Articles

Impact of Modernizing Eligibility Criteria on Enrollment and Representation in Acute Myeloid Leukemia Clinical Trials

Blood blood.2025030741.

https://doi.org/10.1182/blood.2025030741

Published: 2025

Includes: Supplemental data

Journal Articles

Real World Outcomes of Patients (Pts) with Acute Myeloid Leukemia, Myelodysplasia-Related (AML-MR) or Therapy-Related AML (t-AML) Receiving Venetoclax-Based Therapies

Kelly Pugh, Michael C Walker, Deedra Nicolet, Victoria Klein, Krzysztof Mrózek, Gregory K Behbehani, James S. Blachly, Uma Borate, Nicole R. Grieselhuber, Kristin L Koenig, Karilyn T. Larkin, Meixiao Long, Andrew Srisuwananukorn, Ann-Kathrin Eisfeld, Alice Mims

Blood (2024) 144 (Supplement 1): 7929.

https://doi.org/10.1182/blood-2024-210135

Published: 2024

Journal Articles

Transcriptional Regulation of Cytotoxic T-Cell Responses in Acute Myeloid Leukemia

Xufeng Chen, Zhengxi Sun, Jana Elegast, Hua Zhou, Soobeom Lee, Deedra Nicolet, Qiao Lu, Kun Wang, Jun Wang, Wafa Al-Santli, Ann-Kathrin Eisfeld, Kimberly Stegmaier, Iannis Aifantis, Rebecca Austin

Blood (2024) 144 (Supplement 1): 5733.

https://doi.org/10.1182/blood-2024-193591

Published: 2024

Journal Articles

Impact of Socioeconomic Factors on Survival for Adolescent and Young Adult (AYA) Patients (Pts) with Acute Myeloid Leukemia

Andrea Laganson, Victoria Klein, Deedra Nicolet, Aadarsh Teli, Krzysztof Mrózek, Jacob Wareti, Michael C Walker, Christopher Manring, James L Fisher, Electra D Paskett, Elizabeth Ghias, Jesse J Plascak, Alice Mims, Ann-Kathrin Eisfeld, Jill Buss

Blood (2024) 144 (Supplement 1): 7921.

https://doi.org/10.1182/blood-2024-211563

Published: 2024

Journal Articles

Molecular Features of Acute Myeloid Leukemia in Hispanics: An Analysis from the Marrow Consortium

Blood (2024) 144 (Supplement 1): 3801.

https://doi.org/10.1182/blood-2024-212140

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Treatment responses and survival of newly diagnosed older or unfit patients (pts) with IDH1/2-mutated Acute Myeloid Leukemia (AML): An analysis of the MARROW consortium

Loss of the Y chromosome defines a biologically distinct subtype of Acute Myeloid Leukemia (AML), associated with decreased inflammatory response patterns, and favorable outcomes in young male patients (pts)

Accounting for long-term survivors and population-expected survival improves survival outcomes estimation and prediction in older patients with core-binding factor (CBF) Acute Myeloid Leukemia (AML)

Phenotypic shift from primitive to monocytic immunophenotype is unique to patients treated with azacitidine + venetoclax (AZA/VEN) and associated with worse outcomes in AML

Toxicity of reduced dose versus standard dose pegaspargase in adolescents and young adults with acute lymphoblastic leukemia

Characteristics and clinical outcomes of patients (pts) with Acute Myeloid Leukemia (AML) with Mecom rearrangements: An analysis from the MARROW consortium

Defining the clinical characteristics and outcomes of adult patients (pts) with 11q23/KMT2A-rearranged Acute Myeloid Leukemia (AML): An analysis from the MARROW consortium

A randomized study of conventional chemotherapy +/- uproleselan in older adults with Acute Myeloid Leukemia eceiving intensive induction chemotherapy (Alliance A041701)

Evaluation of cytarabine consolidation dosing in older adult patients with Acute Myeloid Leukemia

A multicenter real-world study on response and survival in older patients with acute myeloid leukemia treated with intensive chemotherapy versus VEN/HMA by 2022 and 2024 ELN risk stratifications: An analysis from the MARROW consortium

Deep learning predicts IDH1 mutation status in Acute Myeloid Leukemia from bone marrow smear images

Increased yield of recurrent structural variants (SVs) in Ph-like B-cell acute lymphoblastic leukemia (B-ALL) using a streamlined clinical whole-genome sequencing (WGS) assay

Tri-partied analyses define clinical outcomes and molecular features of patients (pts) with acute promyelocytic leukemia (APL)

Acute myeloid leukemias with UBTF tandem duplications respond to combined BCL-2 and RNA polymerase I inhibition with increased stemness and a quiescent-like state

Exploiting RAS pathway addiction as a therapeutic vulnerability in myeloid sarcoma

Impact of Modernizing Eligibility Criteria on Enrollment and Representation in Acute Myeloid Leukemia Clinical Trials

Real World Outcomes of Patients (Pts) with Acute Myeloid Leukemia, Myelodysplasia-Related (AML-MR) or Therapy-Related AML (t-AML) Receiving Venetoclax-Based Therapies

Transcriptional Regulation of Cytotoxic T-Cell Responses in Acute Myeloid Leukemia

Impact of Socioeconomic Factors on Survival for Adolescent and Young Adult (AYA) Patients (Pts) with Acute Myeloid Leukemia

Molecular Features of Acute Myeloid Leukemia in Hispanics: An Analysis from the Marrow Consortium

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only